Cerebral aneurysm rupture after r-TPA thrombolysis for acute myocardial infarction.
BACKGROUND
Intracranial hemorrhage is the most dreaded risk of thrombolytic therapy for acute myocardial infarction because of the high mortality and disability rates associated with this complication. Brain structural lesions may predispose a patient to bleeding. To date, aneurysm rupture has not been described as a complication of such therapy.


METHODS
A 66-year-old hypertensive woman was admitted because of chest pain. Myocardial infarction was diagnosed and fibrinolytic therapy with recombinant tissue plasminogen activator (r-TPA) was initiated. Eight hours after admission she became unconscious. Brain computed tomography scan showed subarachnoid hemorrhage, and a cerebral arteriography showed an anterior communicating artery aneurysm. Because of her poor clinical condition treatment was postponed. Death occurred 7 days later because of multiorgan failure.


CONCLUSIONS
Cerebral aneurysms should be considered as a possible contributing factor to intracranial bleeding after thrombolytic therapy.
Lagares
A
A
Neurosurgical Service, Hospital 12 de Octubre, Madrid, Spain.
Gómez
P A
PA
Lobato
R D
RD
Alén
J F
JF
Campollo
J
J
Benito-León
J
J
D000368:Aged; D017542:Aneurysm, Ruptured / Q000139:chemically induced* / Q000000981:diagnostic imaging; D002533:Cerebral Angiography; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D002532:Intracranial Aneurysm / Q000139:chemically induced* / Q000000981:diagnostic imaging; D009203:Myocardial Infarction / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D013345:Subarachnoid Hemorrhage / Q000139:chemically induced / Q000000981:diagnostic imaging; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator